Clinical Trial Update: A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS [Phase 1, Phase 2]

View source ↗

Summary

This document updates on a Phase 1/2 study evaluating allogeneic human umbilical cord-derived mesenchymal stem cells with Liberation Therapy for relapsing-remit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Allogeneic Human UC-MSC (umbilical cord-derived mesenchymal stem cells)
• Liberation Therapy

Snippet

Sponsor: Novo Cellular Medicine Institute LLP | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 1, Phase 2 | Status: UNKNOWN